News & Analysis as of

Life Sciences Technology Sector Investment

McDermott Will & Emery

HPE Europe 2024: Key Takeaways

McDermott Will & Emery on

On 19 September 2024, we were once again delighted to assemble hundreds of healthcare professionals, investors, and industry changemakers at The Langham  in London for our annual Healthcare Private Equity (HPE) Europe...more

A&O Shearman

Key takeaways from the LSX World Congress USA

A&O Shearman on

On September 11-12, we had the pleasure of attending the LSX World Congress USA in Boston, where leaders discussed the challenges and opportunities of M&A and partnerships in the pharmaceutical sector....more

Bass, Berry & Sims PLC

Key Takeaways from 2024 Asembia Specialty Pharmacy Summit

Bass, Berry & Sims PLC on

Asembia’s 20th Annual Specialty Pharmacy Summit once again brought investors and operators in the specialty pharmacy ecosystem to Las Vegas for learning sessions and networking. Bass, Berry & Sims brought a team of four...more

Bennett Jones LLP

Investing in R&D-Stage Healthcare Companies: A Recap of BBHIC 2024

Bennett Jones LLP on

It was another record-breaking year for the annual Bloom Burton & Co. Healthcare Investor Conference (BBHIC) in Toronto. The event brought together premier healthcare companies and investors from Canada and around the world....more

Bennett Jones LLP

What’s Hot and What’s Not in Canadian Venture Capital Funding

Bennett Jones LLP on

Key Findings - - U.S. investors show strong and sustained interest - Canadian government-backed funds lead domestic investment - Non-dilutive funding emerges as a dominant force - Majority of investments are in...more

Mintz - Energy & Sustainability Viewpoints

A $1 Billion, 10-year Climate Tech Investment Effort to Come in Massachusetts

As part of the Healey–Driscoll administration’s continued efforts to ensure Massachusetts remains a state where people want to live, work, and raise families — and businesses want to start and operate companies — the...more

McDermott Will & Emery

Innovation in Financing: Where Are We Seeing Growth?

McDermott Will & Emery on

Meanwhile, cash-strapped biotechs have in many cases been forced to leverage relationships with big pharma to address liquidity. Cash is king in a financing environment such as we have observed over the last 18 months, and...more

McDermott Will & Emery

International News: Spotlight on Foreign Investment

McDermott Will & Emery on

In this dynamic global landscape, investors have always been required to make savvy, smart choices. This requires navigating through the intricate web of bilateral treaty protection, exploring the vital role these agreements...more

Wilson Sonsini Goodrich & Rosati

2023 Mid-Year Technology and Life Sciences PIPE and RDO Report

Wilson Sonsini Goodrich & Rosati’s 2023 Mid-Year Technology and Life Sciences PIPE and RDO Report presents analysis related to 87 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by...more

Spilman Thomas & Battle, PLLC

Decoded - Technology Law Insights, V 4, Issue 7, August 2023

You may be Entitled to Financial Compensation…for Your Data - “Without all of our writings and photos that AI companies are using to train their models, they would have nothing to sell.” Why this is important: This...more

Wilson Sonsini Goodrich & Rosati

2022 Technology and Life Sciences IPO Report

In this issue of the 2022 Technology and Life Sciences IPO Report, we present analysis related to 10 initial public offerings (IPOs), valued at over $75 million, completed by U.S.-based technology and life sciences companies...more

Wilson Sonsini Goodrich & Rosati

2022 Technology and Life Sciences PIPE Report

In this inaugural issue of the 2022 Technology and Life Sciences PIPE Report, we present analysis related to 108 private investments in public equity (PIPEs) by U.S.-based technology and life sciences companies between...more

UB Greensfelder LLP

How Silicon Valley Bank's Shutdown Affects Venture Companies

UB Greensfelder LLP on

Among America’s largest banks and formerly well-regarded by analysts, investors, and venture-backed companies alike, the sudden failure of Silicon Valley Bank (SVB) last week sent shockwaves through the venture capital and...more

Fenwick & West LLP

Navigating Uncertain Times: IPO Insights for Late-Stage Technology and Life Sciences Companies - 2023

Fenwick & West LLP on

After 2022’s challenging capital markets environment, leaders in the technology and life sciences industries have set their sights on 2023 and beyond—evaluating the private fundraising market, looking for ways to extend their...more

White & Case LLP

Spotlight on non-horizontal mergers in tech and life sciences sectors

White & Case LLP on

Competition regulators across the world have traditionally perceived non-horizontal mergers as less likely to be problematic because there is substantive scope for efficiencies....more

McDermott Will & Emery

International: Investing in Global Healthcare and Life Sciences - A guide to key legal and regulatory issues in health and life...

Today’s global healthcare marketplace is marked by unprecedented transformation. This presents both challenges and opportunity to today’s market participants. We know how important it is to structure cross-border investments...more

Dechert LLP

UK Life Sciences and Healthcare Newsletter - July 2021: Future Fund: Breakthrough

Dechert LLP on

The British Business Bank (“BBB”) has launched a new fund, whereby the BBB (which is backed by the UK government), will co-invest with certain investors in high-growth, innovative firms. It is called Future Fund: Breakthrough...more

White & Case LLP

Defying gravity: US M&A H1 2019: Pharma chases innovation through deals

White & Case LLP on

The need to replenish intellectual property has pushed the pharma industry to the highest-performing sector by M&A value. In the pharmaceuticals, medical and biotech sector, deal value in the first half of the year was up...more

Fenwick & West Life Sciences Group

JPM Conference Takeaways: Biotech and Biopharma Set for Growth in 2018

Coming off a year that saw a record number of new drug approvals, significant scientific breakthroughs and a year-end tax reform package that both significantly lowers corporate taxes and provides the long-awaited tax...more

19 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide